M Adams

Summary

Affiliation: University Hospital of Wales
Country: UK

Publications

  1. ncbi Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening
    M Adams
    Department of Oncology, Velindre Hospital, Cardiff CF14 2TL, Wales, UK
    Vaccine 25:3007-13. 2007
  2. ncbi Prophylactic HPV vaccination for women over 18 years of age
    M Adams
    Velindre Cancer Centre, Whitchurch, Cardiff, Wales CF14 2TL, UK
    Vaccine 27:3391-4. 2009
  3. ncbi The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer
    M Adams
    Velindre Hospital, Whitchurch, Cardiff and Cardiff University School of Medicine, Cardiff, UK
    Vaccine 23:2374-8. 2005
  4. ncbi Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R)
    M Adams
    Velindre NHS Trust, Velindre Hospital, Whitchurch, Cardiff CF 14 2TL, UK
    Vaccine 21:787-90. 2003
  5. ncbi Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer
    M Adams
    Velindre Hospital, Whitchurch, CF14 2TL, Cardiff, UK
    Vaccine 19:2549-56. 2001
  6. ncbi A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro
    H Navabi
    Velindre Cancer Centre, Velindre NHS Trust, Cardiff, UK
    Vaccine 27:107-15. 2009
  7. ncbi Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial
    H Navabi
    Cancer Services, Velindre NHS Trust, Cardiff, UK
    Blood Cells Mol Dis 35:149-52. 2005
  8. ncbi Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer
    B Jasani
    Departments of Pathology, School of Medicine, Cardiff University, Cardiff, Wales, UK
    Vaccine 27:3401-4. 2009
  9. ncbi Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry
    A Clayton
    Section of Clinical Oncology, University of Wales College of Medicine, Velindre Hospital, Whitchurch, Cardiff CF14 2TL, UK
    J Immunol Methods 247:163-74. 2001
  10. ncbi Simian virus 40 detection in human mesothelioma: reliability and significance of the available molecular evidence
    B Jasani
    Department of Pathology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, Wales, UK
    Front Biosci 6:E12-22. 2001

Collaborators

Detail Information

Publications15

  1. ncbi Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening
    M Adams
    Department of Oncology, Velindre Hospital, Cardiff CF14 2TL, Wales, UK
    Vaccine 25:3007-13. 2007
    ..This may be a particularly sensitive issue for ethnic minority groups. This paper considers the factors which will influence the efficacy of a public HPV vaccination programme and its impact on cervical screening...
  2. ncbi Prophylactic HPV vaccination for women over 18 years of age
    M Adams
    Velindre Cancer Centre, Whitchurch, Cardiff, Wales CF14 2TL, UK
    Vaccine 27:3391-4. 2009
    ..This paper will explore the evidence supporting HPV vaccination in HPV naïve and HPV exposed sexually active women up to 26 years and beyond this age group...
  3. ncbi The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer
    M Adams
    Velindre Hospital, Whitchurch, Cardiff and Cardiff University School of Medicine, Cardiff, UK
    Vaccine 23:2374-8. 2005
    ..The rationale for adopting such a combined approach is discussed here...
  4. ncbi Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R)
    M Adams
    Velindre NHS Trust, Velindre Hospital, Whitchurch, Cardiff CF 14 2TL, UK
    Vaccine 21:787-90. 2003
    ..This strategy is currently being tested in a clinical trial in patients with cervical cancer...
  5. ncbi Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer
    M Adams
    Velindre Hospital, Whitchurch, CF14 2TL, Cardiff, UK
    Vaccine 19:2549-56. 2001
    ..However, further clinical trials are needed to determine the full anti-tumour potential of this vaccine based immunotherapy...
  6. ncbi A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro
    H Navabi
    Velindre Cancer Centre, Velindre NHS Trust, Cardiff, UK
    Vaccine 27:107-15. 2009
    ..These characteristics make poly(I:C12U) a suitable agent for use as an adjuvant in cancer directed immunotherapeutic regimes...
  7. ncbi Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial
    H Navabi
    Cancer Services, Velindre NHS Trust, Cardiff, UK
    Blood Cells Mol Dis 35:149-52. 2005
    ....
  8. ncbi Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer
    B Jasani
    Departments of Pathology, School of Medicine, Cardiff University, Cardiff, Wales, UK
    Vaccine 27:3401-4. 2009
    ....
  9. ncbi Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry
    A Clayton
    Section of Clinical Oncology, University of Wales College of Medicine, Velindre Hospital, Whitchurch, Cardiff CF14 2TL, UK
    J Immunol Methods 247:163-74. 2001
    ..The immuno-magnetic isolation and analysis of exosomes is a versatile and rapid tool for the analysis of APC exosomes, and may prove a valuable tool for the study of exosome biology...
  10. ncbi Simian virus 40 detection in human mesothelioma: reliability and significance of the available molecular evidence
    B Jasani
    Department of Pathology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, Wales, UK
    Front Biosci 6:E12-22. 2001
    ....
  11. ncbi A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group
    M Adams
    Velindre Hospital, Cardiff, England
    Acta Oncol 28:57-60. 1989
    ..Actuarial survival for cisplatin group at 24 months was 50% and for carboplatin group 58% with no significant difference. Carboplatin appears less toxic than cisplatin producing to date similar survival and response as a single agent...
  12. ncbi High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients
    C L Hanna
    Velindre Hospital, Cardiff, UK
    Br J Cancer 72:774-6. 1995
    ..Diarrhoea, nausea, vomiting and mucositis also occurred but were mild and infrequent. Our low response rate may be related to factors such as patient characteristics or duration of treatment...
  13. ncbi Survival in ovarian cancer in Wales: Prior to introduction of all Wales guidelines
    T S Shylasree
    Department of Gynaecological Oncology, Llandough Hospital, Penarth, South Wales, United Kingdom
    Int J Gynecol Cancer 16:1770-6. 2006
    ..022). This study has highlighted the acute issue of the standards of clinical care in the area of ovarian cancer management and will emphasize the implementation of better care pathways for ovarian cancers...
  14. ncbi International Campaign for Cures of Spinal Cord Injury Paralysis (ICCP): another step forward for spinal cord injury research
    M Adams
    1International Spinal Research Trust, Bramley Business Centre, Bramley, Guildford, Surrey, UK
    Spinal Cord 42:273-80. 2004
    ..The mission and objectives of this alliance, termed the International Campaign for Cures of Spinal Cord Injury Paralysis (ICCP), are described here...
  15. ncbi A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer
    A Clamp
    Cancer Research UK Deparment of Medical Oncology, Christie Hospital, M20 4BX, UK
    Gynecol Oncol 95:114-9. 2004
    ..CONCLUSIONS: Exatecan is well tolerated in this poor prognosis group of patients but only has modest single agent activity when administered in a daily regimen...